Analysis Tools
mortality/aging
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease
|
hematopoietic system
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow
|
|
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease
|
|
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit a decrease in myeloid progenitor and myeloid erythrocroid progenitor cells compared with mice reconstituted with wild-type bone marrow
|
|
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• doxycycline-treated mice exhibit an expansion of hematopoietic stem cells (HSCs) due to preferential expansion of short term HSC compared with wild-type mice
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit an increase in HSCs, hematopoietic progenitor cells, and long term HSCs compared with mice reconstituted with wild-type bone marrow
|
|
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
liver/biliary system
|
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
neoplasm
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit an increase in the number of leukemic blasts and infiltration with immature myeloid cells compared with similarly treated wild-type mice reconstituted with wild-type bone marrow
|
immune system
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow
|
|
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease
|
|
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
|
|
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
growth/size/body
|
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow
|
|
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
|
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
|
